News >

Frontline Alectinib Recommended for EU Approval for ALK+ NSCLC

Jason Harris
Published: Friday, Oct 13, 2017

Dr. Sandra Horning

Sandra Horning, MD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of alectinib (Alecensa) for the first-line treatment of adults with ALK-positive, advanced non–small cell lung cancer (NSCLC).

The most common grade ≥3 AEs (≥5%) in the alectinib arm were increased alanine transferase and aspartate transferase (5%) and decreased red blood cells (5%). Patients assigned to crizotinib were more likely to discontinue treatment due to AEs (13% vs 11%), and more likely to experience dose reduction (21% vs 16%) and dose interruption (25% vs 19%).
CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC. Roche. Accessed October 13, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication